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【要約】 
Expression of tenascin-C is a predictor of resistance to anthracycline and taxane chemotherapy 
in patients with triple-negative breast cancer 
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Purpose 
Because resistance to adjuvant chemotherapy by triple-negative breast cancer patients without a beneficial targeted therapy 
is directly linked to poor prognosis, prediction of the resistance before chemotherapy is desired. Here, we showed a 
correlation between chemotherapy resistance and tenascin-c of the extracellular matrix, which served as a niche of the 
stem-like or progenitor properties of breast cancer. 
Methods 
In 133 node-positive breast cancer patients with any subtype who received chemotherapy (Group 1) and 210 triple-negative 
breast cancer patients including 22 neoadjuvant cases (Group 2), we evaluated the correlation of tenascin-c expression 
determined by immunohistochemistry to overall survival and pathological complete response. Furthermore, we evaluated 
the correlation between tenascin-c expression and the IC50 of 4 drugs (doxorubicin, docetaxel, CDDP, and gemcitabine). 
Results 
Overall survival of patients with triple-negative breast cancer with tenascin-c expression, but not without tenascin-c 
expression, was worse than that with non-triple-negative tumors in Group 1. In an analysis of a breast cancer cell line 
database, tenascin-c expression was correlated with chemosensitivity for doxorubicin and gemcitabine. In Group 2, 
tenascin-c expression was a prognostic factor in triple-negative breast cancer patients receiving chemotherapy. Furthermore, 
in a multivariate analysis of patients with anthracycline and taxane neoadjuvant chemotherapy, tenascin-c expression was 
correlated to non-pathological complete response.  
Conclusion 
Tenascin-c expression was correlated to chemotherapy resistance and was an independent prognostic factor in 
triple-negative breast cancer patients who received chemotherapy. We hope that adjuvant chemotherapy can be 
individualized by detecting chemotherapy resistance with tenascin-c immunohistochemistry in triple-negative breast cancer 
patients.     
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